Tumor Biology

, Volume 37, Issue 12, pp 16127–16134 | Cite as

Prognostic risk factors in patients with bone metastasis from colorectal cancer

  • Fangqi Liu
  • Jiang Zhao
  • Jie Xie
  • Li Xie
  • Ji Zhu
  • Sanjun Cai
  • Hongtu Zheng
  • Ye Xu
Original Article


The morbidity of bone metastasis (BM) from colorectal cancer (CRC) is increasing more than ever; however, insufficient research on BM from CRC leads to reduced awareness of the issue. Therefore, the aim of this study was to evaluate the clinical features and prognostic risk factors of CRC patients with BM. Clinical data were retrospectively analyzed for a total of 242 CRC patients with BM. Of the 242 CRC patients with BM, 52 (21.5 %) had bone metastasis alone (BMA) and 190 (78.5 %) had both bone and visceral metastasis (BM&VM). The median survival time (MST) after the diagnosis of BM in all 242 patients was 15.6 months (95 % confidence interval [CI] 12.74–18.46 months). The MST of the BMA group was significantly longer than that of the BM&VM group (29.1 vs. 12.8 months, p = 0.003). Using a Cox proportional hazard model, we identified a high carcinoembryonic antigen (CEA) level and BMA as independent prognostic factors for CRC patients with BM. For the BMA group, the independent prognostic factors were elevated alkaline phosphatase (ALP) and perineural invasion of the primary cancer, which were distinct from the factors for the entire group of BM patients. Furthermore, we found that the BMA patients with multiple sites of BM had similar prognosis to the BM&VM patients. These findings together provide us with a further understanding of BM from CRC and reveal that BMA may be a distinct subset of BM from CRC that has unique independent prognostic factors and a good prognosis.


Colorectal cancer Bone metastasis Prognosis Clinicopathological features 



We thank all the patients whose data were used in this study. This work was supported by the National Natural Science Foundation of China (No. 81472620).

Compliance with ethical standards

Conflicts of interest



  1. 1.
    Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2(8):563–72.CrossRefPubMedGoogle Scholar
  2. 2.
    Kanthan R, Loewy J, Kanthan SC. Skeletal metastases in colorectal carcinomas: a Saskatchewan profile. Dis Colon rectum. 1999;42(12):1592–7.Google Scholar
  3. 3.
    Santini D, Tampellini M, Vincenzi B, Ibrahim T, Ortega C, Virzi V et al. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Annals of oncology: official journal of the European Society forGoogle Scholar
  4. 4.
    Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer. 2005;5(2):108–13.CrossRefPubMedGoogle Scholar
  5. 5.
    Douillard J-Y, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(31):4697–705.CrossRefGoogle Scholar
  6. 6.
    Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Journal of clinical oncology: official journal of the. Proc Am Soc Clin Oncol. 2008;26(12):2013–9.CrossRefGoogle Scholar
  7. 7.
    Van Cutsem E, Köhne C-H, Hitre E, Zaluski J, Chang Chien C-R, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17.CrossRefPubMedGoogle Scholar
  8. 8.
    Besbeas S, Stearns MW. Osseous metastases from carcinomas of the colon and rectum. Dis Colon rectum. 1978;21(4):266–8.Google Scholar
  9. 9.
    Nozue M, Oshiro Y, Kurata M, Seino K-I, Koike N, Kawamoto T, et al. Treatment and prognosis in colorectal cancer patients with bone metastasis. Oncol Rep. 2002;9(1):109–12.PubMedGoogle Scholar
  10. 10.
    Harries M, Taylor A, Holmberg L, Agbaje O, Garmo H, Kabilan S, et al. Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients. Cancer Epidemiol. 2014;38(4):427–34.CrossRefPubMedGoogle Scholar
  11. 11.
    Qiu M, Hu J, Yang D, Cosgrove DP, Xu R. Pattern of distant metastases in colorectal cancer: a SEER based study. Oncotarget. 2015;6(36):38658–66.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Gutman M, Fidler IJ. Biology of human colon cancer metastasis. World J Surg. 1995;19(2):226–34.CrossRefPubMedGoogle Scholar
  13. 13.
    Takagawa R, Fujii S, Ohta M, Nagano Y, Kunisaki C, Yamagishi S, et al. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol. 2008;15(12):3433–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon rectum. 1994;37(3):272–7.Google Scholar
  15. 15.
    Rama N, Monteiro A, Bernardo JE, Eugénio L, Antunes MJ. Lung metastases from colorectal cancer: surgical resection and prognostic factors. European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery. 2009;35(3):444–9.CrossRefGoogle Scholar
  16. 16.
    Regnard JF, Grunenwald D, Spaggiari L, Girard P, Elias D, Ducreux M, et al. Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg. 1998;66(1):214–8 - discussion 8-9.CrossRefPubMedGoogle Scholar
  17. 17.
    Farley JR, Baylink DJ. Skeletal alkaline phosphatase activity as a bone formation index in vitro. Metab Clin Exp. 1986;35(6):563–71.CrossRefPubMedGoogle Scholar
  18. 18.
    Mountzios G, Ramfidis V, Terpos E, Syrigos KN. Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data. Clinical lung cancer. 2011;12(6):341–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Liebig C, Ayala G, Wilks JA, Berger DH, Albo D. Perineural invasion in cancer: a review of the literature. Cancer. 2009;115(15):3379–91.CrossRefPubMedGoogle Scholar
  20. 20.
    Kim HR, Min BS, Kim JS, Shin SJ, Ahn JB, Rho JK, et al. Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis. Oncology. 2011;81(3–4):175–83.CrossRefPubMedGoogle Scholar
  21. 21.
    Delva R, Pein F, Lortholary A, Gamelin E, Cellier P, Larra F. [bone metastases of colorectal cancers: apropos of 8 cases]. La Revue de Médecine Interne. 1993;14(4):223–8.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  1. 1.Department of Colorectal SurgeryFudan University Shanghai Cancer CenterShanghaiChina
  2. 2.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina
  3. 3.Department of Medical OncologyFudan University Shanghai Cancer CenterShanghaiChina
  4. 4.Clinical Statistics CenterFudan University Shanghai Cancer CenterShanghaiChina
  5. 5.Department of Radiation OncologyFudan University Shanghai Cancer CenterShanghaiChina

Personalised recommendations